Fortress Historical Cash Flow
| FBIO Stock | USD 1.65 0.08 4.62% |
Analysis of Fortress Biotech cash flow over time is an excellent tool to project Fortress Biotech future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as End Period Cash Flow of 116.5 M or Change To Liabilities of 56 M as it is a great indicator of Fortress Biotech ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Fortress Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Fortress Biotech is a good buy for the upcoming year.
Fortress |
About Fortress Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Fortress balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Fortress's non-liquid assets can be easily converted into cash.
Fortress Biotech Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most accounts from Fortress Biotech's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Fortress Biotech current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fortress Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Fortress Stock, please use our How to Invest in Fortress Biotech guide.At this time, Fortress Biotech's Change To Account Receivables is very stable compared to the past year. As of the 28th of March 2025, Change To Netincome is likely to grow to about 19.2 M, while Capital Expenditures is likely to drop about 68.8 K.
Fortress Biotech cash flow statement Correlations
Click cells to compare fundamentals
Fortress Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Fortress Biotech cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Capital Expenditures | 7.2M | 16.3M | 3.1M | 63K | 72.5K | 68.8K | |
| Total Cash From Financing Activities | 172.4M | 149.0M | 75.3M | 32.7M | 37.6M | 35.8M | |
| End Period Cash Flow | 235.0M | 308.0M | 181.0M | 83.4M | 95.9M | 116.5M | |
| Change To Liabilities | 4.7M | 2.7M | 6.5M | 46.3M | 53.3M | 56.0M | |
| Sale Purchase Of Stock | (70K) | 24.3M | (1.2M) | (400K) | (460K) | (437K) | |
| Change In Cash | 81.6M | 73.0M | (127.0M) | (97.6M) | (87.8M) | (83.4M) | |
| Stock Based Compensation | 13.5M | 19.5M | 23.0M | 17.0M | 19.6M | 12.6M | |
| Free Cash Flow | (90.8M) | (132.9M) | (182.5M) | (136.3M) | (122.7M) | (116.6M) | |
| Change In Working Capital | (4.8M) | 36.4M | (715K) | (12.5M) | (14.4M) | (13.7M) | |
| Begin Period Cash Flow | 153.4M | 235.0M | 308.0M | 181.0M | 208.1M | 118.0M | |
| Other Cashflows From Financing Activities | 90.8M | (5.4M) | 47.7M | (2.0M) | (2.3M) | (2.2M) | |
| Depreciation | 5.3M | 6.8M | 9.4M | 6.0M | 6.9M | 7.2M | |
| Other Non Cash Items | 10.5M | 24.4M | 2.9M | (78.1M) | (70.3M) | (66.8M) | |
| Total Cash From Operating Activities | (83.7M) | (116.5M) | (179.4M) | (128.2M) | (115.4M) | (109.6M) | |
| Net Income | (103.0M) | (164.8M) | (213.9M) | (60.6M) | (54.6M) | (57.3M) | |
| Change To Inventory | (547K) | (8.5M) | 1.7M | 4.0M | 3.6M | 3.7M | |
| Total Cashflows From Investing Activities | 18.8M | 20.1M | (7.2M) | 40.5M | 46.6M | 48.9M | |
| Dividends Paid | 2.6M | 6.8M | 8.8M | 8.8M | 10.1M | 10.6M | |
| Change To Account Receivables | (5.9M) | 768K | (5.4M) | 12.5M | 14.4M | 15.1M | |
| Other Cashflows From Investing Activities | (5.2M) | (11.8M) | 127K | (2.0M) | (1.8M) | (1.7M) | |
| Change To Netincome | (1.8M) | 13.3M | (43.3M) | 20.3M | 18.3M | 19.2M | |
| Investments | (7.2M) | 56.9M | (22.9M) | (2.4M) | (2.8M) | (2.7M) | |
| Net Borrowings | 1K | 14.7M | (29.7M) | (15.0M) | (13.5M) | (12.9M) | |
| Change To Operating Activities | (680K) | 1.5M | (5.0M) | (2.2M) | (2.0M) | (2.1M) | |
| Issuance Of Capital Stock | 224.9M | 172.2M | 43.0M | 71.0M | 63.9M | 92.5M |
Pair Trading with Fortress Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Fortress Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fortress Biotech will appreciate offsetting losses from the drop in the long position's value.Moving together with Fortress Stock
Moving against Fortress Stock
| 0.8 | WM | Waste Management | PairCorr |
| 0.7 | LUCD | Lucid Diagnostics | PairCorr |
| 0.68 | GE | GE Aerospace | PairCorr |
| 0.6 | PG | Procter Gamble | PairCorr |
| 0.4 | PLX | Protalix Biotherapeutics | PairCorr |
The ability to find closely correlated positions to Fortress Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Fortress Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Fortress Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Fortress Biotech to buy it.
The correlation of Fortress Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Fortress Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Fortress Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Fortress Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fortress Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Fortress Stock, please use our How to Invest in Fortress Biotech guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fortress Biotech. If investors know Fortress will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fortress Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Revenue Per Share | Quarterly Revenue Growth (0.07) | Return On Assets | Return On Equity |
The market value of Fortress Biotech is measured differently than its book value, which is the value of Fortress that is recorded on the company's balance sheet. Investors also form their own opinion of Fortress Biotech's value that differs from its market value or its book value, called intrinsic value, which is Fortress Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fortress Biotech's market value can be influenced by many factors that don't directly affect Fortress Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fortress Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fortress Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fortress Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.